Weekly Recap: Q2 revenue/EPS estimates and treasury share holdings

Novo Nordisk A/S Sponsored ADR Class B (OMXCOP:NOVO_B) faces a mixed outlook as Q2 results due in early August — with ~DKK71.5bn revenue and DKK5.04 EPS estimates tied to Wegovy/Zepbound rollouts and CagriSema updates — even as a Phase 3 anti‑inflammatory trial failed and a May buyback boosted treasury B shares to ~1%.

Previous Week Recap

• Novo Nordisk A/S Sponsored ADR Class B Q2 Revenue, EPS: Novo Nordisk (NOVO_B) Q2 results due early August; traders watch ~DKK71.5bn revenue and DKK5.04 EPS estimates, sales of Wegovy/Zepbound, Europe oral rollout and CagriSema updates.
• Novo Nordisk A/S Sponsored ADR Class B Buyback: Novo Nordisk (NOVO_B) launched a share buyback program in May 2026, has repurchased B shares, and currently holds 43,104,480 treasury B shares representing about 1% of capital.
• Phase 3 Trial Fail To Meet Endpoint: Novo Nordisk (NOVO_B) said its Phase 3 anti‑inflammatory trial failed to meet the primary endpoint: no significant reduction in major adverse cardiovascular events in high‑risk patients.

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.